Galvus Met 50/850mg 10pcs

Galvus Met 50mg/850mg is a potent combination therapy for Type 2 Diabetes Mellitus, uniting two antihyperglycemic agents: Metformin and Vildagliptin. This synergistic formulation offers comprehensive glycemic control through complementary mechanisms:

• Metformin: A biguanide that reduces hepatic glucose production and enhances peripheral glucose uptake, improving insulin sensitivity.
• Vildagliptin: A DPP-4 inhibitor that increases incretin levels, stimulating insulin secretion and suppressing glucagon release postprandially.

Dosage and Administration:

Initiate Galvus Met 50mg/850mg based on the patient’s current Metformin dosage. Typically, one tablet is administered twice daily with meals to reduce gastrointestinal side effects. The maximum recommended daily dose is 100mg of Vildagliptin and 2000mg of Metformin. Adjustments should be individualized based on efficacy and tolerability.

Drug Interactions:

Co-administration with other antidiabetic agents may enhance the hypoglycemic effect. Notably, Vildagliptin has a low potential for drug interactions as it neither inhibits nor induces cytochrome P450 enzymes. However, caution is advised when combining with medications that may affect renal function or have significant renal excretion.

Contraindications:

• Known hypersensitivity to Vildagliptin, Metformin, or any excipients.
• Patients with renal impairment (e.g., serum creatinine levels ≥1.5 mg/dL in males, ≥1.4 mg/dL in females) due to the risk of lactic acidosis.
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.

Side Effects:

Common adverse reactions include:

• Gastrointestinal disturbances: Nausea, vomiting, diarrhea, and abdominal discomfort.
• Central nervous system effects: Headache, dizziness, and tremors.
• Hypoglycemia: Especially when used in combination with other antidiabetic medications.

Pregnancy and Lactation:

The use of Galvus Met 50mg/850mg during pregnancy is not recommended due to limited human data. Animal studies have shown reproductive toxicity with Vildagliptin. It is unknown whether Vildagliptin or Metformin is excreted in human milk; therefore, a decision should be made to discontinue nursing or discontinue the drug, considering the importance to the mother.

Precautions and Warnings:

• Lactic Acidosis: A rare but serious complication associated with Metformin accumulation. Risk factors include renal dysfunction, concomitant use of nephrotoxic agents, and conditions associated with hypoxemia.
• Hepatic Impairment: Not recommended in patients with hepatic dysfunction due to the risk of elevated transaminases and potential for lactic acidosis.
• Regular Monitoring: Assess renal function before initiation and periodically thereafter. Liver function tests should be performed initially and during treatment to detect hepatic abnormalities.

Incorporating these targeted keywords and detailed information aims to improve the visibility of Galvus Met 50mg/850mg in search engine results, thereby reaching a broader audience seeking effective solutions for managing Type 2 Diabetes Mellitus.

Note: Always consult healthcare professionals for personalized medical advice.